Medicon Valley Biomedical Newsletter

The Danish Centre for Translational Breast Cancer Research, DCTB, has announced the creation of a network of breast cancer researchers to break the steady increase in breast cancer within the next 5 y...

Novo Nordisk A/S has donated EUR 79 million to Danish basic research. The donation gives new hope of being able to provide much more targeted and effective treatment of many diseases, including cancer...

Alligator Bioscience AB has launched FINDbind, a method for antibody optimization. FINDbind is based on Alligator Bioscience's proprietary platform of technologies for protein evolution, and is tailor...

BioGaia AB has signed another agreement with Sunstar Suisse SA, giving Sunstar an exclusive option to distribute BioGaia's oral health products in a large number of countries globally. Suns...

Camurus AB has received approval to initiate a Phase I/II clinical trial of CAM2032, the company's long-acting luteinising hormone-releasing hormone, LHRH, agonist therapy for prostate cancer. The...

CellaVision AB has received its largest Nordic order to date. CellaVision DM analyzers for routine analysis of blood will be installed at four of the Karolinska University Laboratory sites for clinica...

European Institute of Science AB, Euris, is planning to establish a new incubator in Lund. The company has acquired a site with the purpose to build a novel research centre, and large enough to house ...

LifeCycle Pharma A/S has announced the issuance of a patent for its MeltDose Technology by the US Patent and Trademark Office. The patent covers the method of making a particulate material containing ...

LifeCycle Pharma A/S has announced that it has signed an exclusive license agreement with Sciele Pharma, Inc. to market fenofibrate in the US, Canada, and Mexico, in 120 milligram and 40 milligram str...

MIP Technologies AB and Supelco, have announced the launch of a new solid phase extraction product for the selective extraction of tobacco- specific nitrosamines, TSNAs. The SupelMIP TSNA cartr...

Under their strategic alliance with NeuroSearch A/S, GlaxoSmithKline, GSK, has initiated the second of two studies in a Phase II development programme with the drug candidate NS2359, GSK372475 in pati...

Novozymes A/S, the biotech-based world leader in enzymes and microorganisms, has announced the creation of a new Biopharmaceutical Ingredients business, which will develop and manufacture animal free ...

Pharmexa-Epimmune and Bavarian Nordic have announced the initiation of a Phase I trial testing two HIV vaccines EP1233 and MVA-BN Polytope in combination. The clinical trial will be conducted by the H...

Pharmexa A/S has announced that the FDA has approved their application to start the PrimoVax trial in the United States. Pharmexa expects the first American pancreas cancer patient to be treated with ...

Phaseonetrials A/S has been listed on First North, the small and medium enterprise list of the Copenhagen Stock Exchange. Between 1.3 and 1.68 million shares are for sales, at EUR 5.2 each, rendering ...

SpectraCure AB will receive EUR 3.5 million from Industrifonden, Ostersjöstiftelsen and Karolinska Development II. The money is to be used for a clinical study of the treatment of prostate cancer by p...

TopoTarget A/S has announced that a new Phase II clinical trial has been initiated, testing Avugane, a topical valproic acid - an HDAC inhibitor drug - in the treatment of acne vulgaris. This double-b...

A new vaccine for meningitis is to be tested in Europe for the first time. To establish if meningitis and septicemia can be prevented amongst children and young people a research group at University H...